药物治疗管理对慢性结石性胆囊炎患者临床治疗的影响

Impact of Drug Therapy Management on the Clinical Treatment of Patients with Chronic Calculus Cholecystitis

目的:分析和评估药物治疗管理对慢性结石性胆囊炎患者临床治疗的影响,为药物治疗管理在慢病管理中的应用提供参考。方法:选取2021年10月1日—2022年6月31日医院收治的100例慢性结石性胆囊炎患者作为研究对象,所有患者均接受正常的临床治疗,但根据是否开展药物治疗管理将其分为传统组(50例)和药学组(50例),比较2组患者治疗期间的用药依从性、治疗后的溶石率,以及治疗前后总胆红素(total bilirubin,TBil)、总胆固醇(total cholesterol,TC)和总胆汁酸(total bile acid,TBA)等重要指标的变化情况。结果:药学组患者治疗后的总溶石率高于传统组(86.00%vs 68.00%,P<0.05);药学组患者治疗期间用药依从性的改善情况显著优于传统组(P<0.05);2组患者治疗后TBil和TC的水平均低于治疗前(P<0.05),但药学组患者的改善程度明显优于传统组(P<0.05);2组患者治疗后的腹痛评分均低于治疗前(P<0.05),但药学组患者的下降程度显著大于传统组(P<0.05);治疗期间,药学组患者药物不良反应的发生率略低于传统组(14.00%vs 20.00%),但经比较其差异无统计学意义(P>0.05)。结论:药物治疗管理可以较好地改善慢性结石性胆囊炎患者的用药依从性,使患者治疗更加规范,从而促进患者各项指标和症状的恢复。

Objective:To analyze and evaluate the impact of drug therapy management on the clinical treatment of patients with chronic calculus cholecystitis and provide reference for the application of drug therapy management in chronic disease management.Methods:A total of 100 patients with chronic calculus cholecystitis admitted to the hospital from October 1,2021 to June 31,2022 were selected as research subjects.All patients received normal clinical treatment,but they were divided into the traditional group(50 patients) and the pharmaceutical group(50 patients) based on whether the drug therapy management was implemented,and the patients in the two groups were compared in terms of medication compliance during treatment,litholysis rate after treatment,and total bilirubin(TBil),total cholesterol(TC) and total bile acid(TBA) before and after treatment,etc.Results:The total litholysis rate of patients in the pharmaceutical group after treatment was higher than that of the traditional group(86.00% vs 68.00%,P<0.05);the improvement in medication compliance of patients in the pharmaceutical group during treatment was significantly superior to the traditional group(P<0.05);the levels of TBil and TC in the two groups of patients after treatment were lower than those before treatment(P<0.05),but the degree of improvement of the patients in the pharmaceutical group was significantly superior to the traditional group(P<0.05);the abdominal pain scores of the patients in the two groups after treatment were lower than those before treatment(P<0.05),but the degree of decline in the pharmaceutical group was significantly higher than that in the traditional group(P<0.05);during treatment,the incidence rate of adverse drug reactions in the pharmaceutical group was slightly lower than that in the traditional group(14.00% vs 20.00%).However,upon comparation,the difference was not statistically significant(P>0.05).Conclusion:The drug therapy management can better improve the medication compliance of patients with chronic calculus cholecystitis,make the treatment of patients more standardized,and thus promote the recovery of various indicators and symptoms of patients.